To investigate the attenuating effect of Hydroxysafflor yellow A (HSYA) on inflammatory injury in chronic obstructive pulmonary disease (COPD).
Rats were randomly assigned to 7 groups according to body weight including normal control group, HSYA blank group (76.8 mg/kg), COPD group, COPD+HSYA (30, 48, 76.8 mg/kg) groups and COPD+dexamethasone (2 mg/kg), 10 in each group. Passive cigarette smoke and intratracheal instillation of lipopolysaccharides were used to establish a COPD model in rats. Hematoxylin and eosin staining of lung tissue sections was used, real-time polymerase chain reaction (PCR) was used to assay mRNA levels of some cytokines in lung tissues, the cytokines in bronchoalveolar lavage fluid (BALF) were measured by enzyme-linked immunosorbent assay (ELISA), Western blot analysis was used to determine phosphorylated p38 mitogen-activated protein kinase (MAPK) levels in lung tissues, and nuclear factor-κB (NF-κB) p65 protein levels in lung tissues were detected by immunohistochemistry.
Lung alveolar septa destruction, alveolus fusion, inflammatory cell infiltration, and bronchiole exudation were observed. These pathological changes were alleviated in the COPD+HSYA group. The mRNA expression of inflammatory factors were significantly increased in lung tissues from COPD rats (all P<0.01) and were inhibited by HSYA. Levels of inflammatory cytokines in BALF of COPD rats were significantly increased (all P<0.01) which were inhibited by HSYA (all P<0.01, 48, 76.8 mg/kg). The levels of p38 MAPK phosphorylation and p65 in lung tissues of COPD rats were significantly increased (all P<0.01) and were suppressed by HSYA (all P<0.01, 48, 76.8 mg/kg).
HSYA could alleviate inflammatory cell infiltration and other pathological changes in the lungs of COPD rats. HSYA inhibited inflammatory cytokine expression, and increase phosphorylation of p38 MAPK and NF-κB p65 in the lungs of COPD rats. The protective mechanism of HSYA to inhibit COPD inflammation might be by attenuating NF-κB and p38MAPK signal transduction.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Vestbo J, Hurd SS, Agustí AG, Jones PW, Vogelmeier C, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2013;187:347–365.
Chinese Society of Respiratory Diseases, Guideline for diagnosis and management of COPD (Revised in 2007). Chin J Tuberc Respir Dis (Chin) 2007;30:8-17.
Lopez AD, Shibuya K, Rao C, Mathers CD, Hansell AL, Held LS, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur Respir J 2006;27:397–412.
Barnes PJ. The cytokine network in asthma and chronic obstructive pulmonary disease. J Clin Invest 2008;118:3546–3556.
Wang HL. Modern study review of Safflor Yellow. Chin J Tradit Med Sci Technol 1998;5:333–334.
Feng ZM, He J, Jiang JS, Chen Z, Yang YN, Zhang PC. NMR solution structure study of the representative component hydroxysafflor yellow A and other quinochalcone C-glycosides from Carthamus tinctorius. J Nat Prod 2013;76:270–274.
Sun CY, Pei C, Zang BX, Wang L, Jin M. The ability of hydroxysafflor yellow A to attenuate lipopolysaccharideinduced pulmonary inflammatory injury in mice. Phytother Res 2010;24:1788–1795.
Wang Y, Xue CJ, Dong F, Peng YY, Zhang YD, Jin M, et al. Hydroxysafflor yellow A attenuates small airway remodeling in a rat model of chronic obstructive pulmonary disease. Biol Pharm Bull 2014;37:1591–1598.
Gaschler G, Bauer C, Zavitz C, Stämpfli M. Animal models of chronic obstructive pulmonary disease exacerbations, models of exacerbations in asthma and COPD. Contrib Microbiol Basel Karger 2007;14:126–141.
Zang BX, Jin M, Li JR. Large scale preparation of pure hydroxysafflor yellow A by macroporus resin-gel column chromatography. J Cardiovasc Pulm Dis 2008,27:363–365.
Barbu C, Iordache M, Man MG. Inflammation in COPD: pathogenesis, local and systemic effects. Rom J Morphol Embryol 2011;52:21–27.
Vernooy JHJ, Dentener MA, van Suylen RJ, Buurman WA, Wouters EF. Long-term intratracheal lipopolysaccharide exposure in mice results in chronic lung inflammation and persistent pathology. Am J Respir Cell Mol Biol 2002;26:152–159.
Li HM, Cui DJ, Tong X, Pang BS, Gao YB, Wang DW. Establishment of chronic obstructive pulmonary disease rat models by passive cigarette smoking and intratracheal instillation of lipopolysaccharide. Chin J Pathophysiol (Chin) 2002;18:808–812.
Pei CQ, Sun CY, Jin M. Mitigation of safflor yellow injection on acute lung injury of rats induced by oleic acid. Chin Tradit Herb Drugs (Chin) 2010;41:597–601.
Fan J, Richard DY, Malik AB. Transcriptional mechanisms of acute lung injury. Am J Lung Cell Mol Physiol 2001;281:L1037–L1050.
Hudry-Clergeon H, Stengel D, Ninio E, Vilgrain I. Platelet-activating factor increases VE-cadherin tyrosine phosphorylation in mouse endothelial cells and its association with the PtdIns3'-kinase. FASEB J 2005;19:512–520.
Zhang Q, Chen ZY, Wu LB, Wang SC, Zheng QS. Clinical non-feriority evaluation on the efficacy and safety of safflower yellow pigment lyophilized power & dripping solution in the treatment of patients with angina. Chin J Evid-Based Med 2005;15:276–285.
Wang L, Jin M, Zang BX, Wu Y. Inhibitory effect of Safflor Yellow on pulmonary fibrosis. Biol Pharm Bull 2011;34:511–516.
Supported by the National Natural Science Foundation of China (No. 81270103), the Natural Science Foundation of Beijing (No. 7132047), and the Project of Integrated Traditional Chinese Medicine-Western Medicine Institute of Heart Lung and Blood Vessel Diseases
About this article
Cite this article
Jin, M., Xue, C., Wang, Y. et al. Protective Effect of Hydroxysafflor Yellow A on Inflammatory Injury in Chronic Obstructive Pulmonary Disease Rats. Chin. J. Integr. Med. 25, 750–756 (2019). https://doi.org/10.1007/s11655-018-2577-2
- Hydroxysafflor yellow A
- chronic obstructive pulmonary disease
- p38 mitogen-activated protein kinase
- nuclear factor-κB